经导管三尖瓣介入治疗:现有设备和临床证据

IF 2.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Xiaoping Ning MD , Hongjie Xu MD , Jingyi Cao MD , Ning Li MD , Wei Wang MD , Fan Qiao MD, PhD , Lin Han MD, PhD , Fanglin Lu MD, PhD , Zhiyun Xu MD, PhD
{"title":"经导管三尖瓣介入治疗:现有设备和临床证据","authors":"Xiaoping Ning MD ,&nbsp;Hongjie Xu MD ,&nbsp;Jingyi Cao MD ,&nbsp;Ning Li MD ,&nbsp;Wei Wang MD ,&nbsp;Fan Qiao MD, PhD ,&nbsp;Lin Han MD, PhD ,&nbsp;Fanglin Lu MD, PhD ,&nbsp;Zhiyun Xu MD, PhD","doi":"10.1016/j.jjcc.2024.04.001","DOIUrl":null,"url":null,"abstract":"<div><p>The tricuspid valve is known as “the forgotten valve”. Tricuspid regurgitation (TR) is a highly prevalent valvular heart disease. TR is often late in the course of the disease when it becomes symptomatic, often being a marker of late-stage chronic heart failure with a poor prognosis and high mortality rate at long-term follow-up. Despite the clear correlation between TR and mortality, most TR patients are under-treated. Neither pharmacologic nor surgical treatment demonstrates a significant survival benefit. Isolated tricuspid valve surgery has the highest mortality rate of all valve surgeries. Therefore, there is an urgent clinical need for minimally invasive therapies to meet the needs of patients with TR. In recent years, a variety of transcatheter tricuspid valve interventions representing less invasive alternatives to surgery have shown promising results, which bring hope to patients with severe TR. The purpose of this review is to provide a complete and updated overview on current transcatheter tricuspid valve interventions and clinical evidence.</p></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"84 2","pages":"Pages 73-79"},"PeriodicalIF":2.5000,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transcatheter tricuspid valve interventions: Current devices and clinical evidence\",\"authors\":\"Xiaoping Ning MD ,&nbsp;Hongjie Xu MD ,&nbsp;Jingyi Cao MD ,&nbsp;Ning Li MD ,&nbsp;Wei Wang MD ,&nbsp;Fan Qiao MD, PhD ,&nbsp;Lin Han MD, PhD ,&nbsp;Fanglin Lu MD, PhD ,&nbsp;Zhiyun Xu MD, PhD\",\"doi\":\"10.1016/j.jjcc.2024.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The tricuspid valve is known as “the forgotten valve”. Tricuspid regurgitation (TR) is a highly prevalent valvular heart disease. TR is often late in the course of the disease when it becomes symptomatic, often being a marker of late-stage chronic heart failure with a poor prognosis and high mortality rate at long-term follow-up. Despite the clear correlation between TR and mortality, most TR patients are under-treated. Neither pharmacologic nor surgical treatment demonstrates a significant survival benefit. Isolated tricuspid valve surgery has the highest mortality rate of all valve surgeries. Therefore, there is an urgent clinical need for minimally invasive therapies to meet the needs of patients with TR. In recent years, a variety of transcatheter tricuspid valve interventions representing less invasive alternatives to surgery have shown promising results, which bring hope to patients with severe TR. The purpose of this review is to provide a complete and updated overview on current transcatheter tricuspid valve interventions and clinical evidence.</p></div>\",\"PeriodicalId\":15223,\"journal\":{\"name\":\"Journal of cardiology\",\"volume\":\"84 2\",\"pages\":\"Pages 73-79\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-04-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0914508724000601\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0914508724000601","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

三尖瓣被称为 "被遗忘的瓣膜"。三尖瓣反流(TR)是一种高发的瓣膜性心脏病。三尖瓣反流通常在病程晚期才出现症状,通常是晚期慢性心力衰竭的标志,预后差,长期随访死亡率高。尽管 TR 与死亡率之间存在明显的相关性,但大多数 TR 患者都未得到充分治疗。无论是药物治疗还是手术治疗,都不能明显提高患者的生存率。在所有瓣膜手术中,孤立的三尖瓣手术死亡率最高。因此,临床迫切需要微创疗法来满足 TR 患者的需求。近年来,各种经导管三尖瓣介入治疗代表了手术的微创替代疗法,取得了可喜的成果,为严重 TR 患者带来了希望。本综述旨在提供有关当前经导管三尖瓣介入疗法和临床证据的最新完整概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Transcatheter tricuspid valve interventions: Current devices and clinical evidence

Transcatheter tricuspid valve interventions: Current devices and clinical evidence

Transcatheter tricuspid valve interventions: Current devices and clinical evidence

The tricuspid valve is known as “the forgotten valve”. Tricuspid regurgitation (TR) is a highly prevalent valvular heart disease. TR is often late in the course of the disease when it becomes symptomatic, often being a marker of late-stage chronic heart failure with a poor prognosis and high mortality rate at long-term follow-up. Despite the clear correlation between TR and mortality, most TR patients are under-treated. Neither pharmacologic nor surgical treatment demonstrates a significant survival benefit. Isolated tricuspid valve surgery has the highest mortality rate of all valve surgeries. Therefore, there is an urgent clinical need for minimally invasive therapies to meet the needs of patients with TR. In recent years, a variety of transcatheter tricuspid valve interventions representing less invasive alternatives to surgery have shown promising results, which bring hope to patients with severe TR. The purpose of this review is to provide a complete and updated overview on current transcatheter tricuspid valve interventions and clinical evidence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of cardiology
Journal of cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.90
自引率
8.00%
发文量
202
审稿时长
29 days
期刊介绍: The official journal of the Japanese College of Cardiology is an international, English language, peer-reviewed journal publishing the latest findings in cardiovascular medicine. Journal of Cardiology (JC) aims to publish the highest-quality material covering original basic and clinical research on all aspects of cardiovascular disease. Topics covered include ischemic heart disease, cardiomyopathy, valvular heart disease, vascular disease, hypertension, arrhythmia, congenital heart disease, pharmacological and non-pharmacological treatment, new diagnostic techniques, and cardiovascular imaging. JC also publishes a selection of review articles, clinical trials, short communications, and important messages and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信